Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
| Status: | Terminated |
|---|---|
| Conditions: | Diabetes, Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/20/2018 |
| Start Date: | January 2014 |
| End Date: | August 2016 |
This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in
patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will
receive Sitagliptin or placebo. Sitagliptin may be of particular use in this patient
population due to the effects on hepatic glucose production (a major feature of SH), safety
(lack of contra-indications for heart failure or renal failure and no hypoglycemia), and
tolerability. The secondary objective of this study is to determine whether the management of
patients with persistent insulin requirements following cardiac surgery differs among
patients with stress hyperglycemia or mild diabetes.
patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will
receive Sitagliptin or placebo. Sitagliptin may be of particular use in this patient
population due to the effects on hepatic glucose production (a major feature of SH), safety
(lack of contra-indications for heart failure or renal failure and no hypoglycemia), and
tolerability. The secondary objective of this study is to determine whether the management of
patients with persistent insulin requirements following cardiac surgery differs among
patients with stress hyperglycemia or mild diabetes.
Inclusion Criteria:
- Either of the following: Mild Diabetes Mellitus or Stress Hyperglycemia
- AND:
- Cardiac Surgery
- Insulin Requirement between 8-30 units subcutaneous on post-op day 3 or later off
pressors, off enteral feeding, extubated OR glucose >150 mg/dL at least twice in a 24
hour period (>4 hours apart) and otherwise not requiring basal insulin
Exclusion Criteria:
- use of pressors, mechanical ventilation, or enteral or parenteral feeding within
previous 12 hours
- glucocorticoids in doses exceeding the equivalent of Prednisone 10 mg/day within the
previous 48 hours
- left ventricular assist device
- percutaneous or laparoscopic surgery
- end stage renal disease
- end stage liver disease
- history of pancreatitis
- type 1 diabetes
- pregnancy
- unable to give consent in english
- no phone
- prisoners
- less than 18 years of age
We found this trial at
1
site
410 W 10th Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(614) 293-8652
Phone: 614-688-6885
The Ohio State University, Wexner Medical Center Located in Columbus, The Ohio State University Wexner...
Click here to add this to my saved trials
